ReviewJournal of the American Heart Association2025
Improving Representation of Underserved Populations in Cardiovascular Research.
Review in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Within the United States, cardiovascular disease is the leading cause of death. There are well-established inequities in cardiovascular care; individuals from medically underserved populations-including those with low socioeconomic status, rural populations, a plethora of racial and ethnic groups, women, and those living with disabilities-are often at increased risk of cardiovascular morbidity and mortality. Despite their critically unmet needs, these populations remain underrepresented within cardiovascular clinical trials, therefore deepening inequities in cardiovascular care. The inclusion of representative populations within cardiovascular clinical research ensures that data derived from clinical trials translate into effectiveness for all populations, particularly as cardiovascular therapeutics move toward personalized approaches. In this article, we review the importance of including underserved populations in cardiovascular clinical research and the key barriers to their participation. We explore system-level strategies that have only recently demonstrated large-scale feasibility within the cardiovascular research paradigm, such as community-engaged research and clinical trial decentralization, to increase access and engage underserved communities. Decentralizing clinical trials can overcome many of the barriers associated with performing clinical trials at traditional study sites. Additionally, increasing clinical trial workforce diversity and including community clinicians and stakeholders during study design, recruitment, and administration can improve representation within clinical trials. Finally, we propose a holistic approach to improving the diversity of cardiovascular clinical trial participants through the application of the hub-and-spoke organizational model.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.